How Tariffs Created a $19bn Pharma Crisis
Pharma’s supply chain crisis crystallised in early 2025 when the United States implemented sweeping tariffs on pharmaceutical imports, creating immediate financial pressures and strategic imperatives that continue to reverberate. These proposed tariffs could cost the generic and biosimilar medicines industry heavily over the next ten years, threatening patients’ ability to access affordable medicines, and undermining the sustainability of the already precarious healthcare system.
While the resulting cost increases are significant, they’re by no means the most significant outcome of these tariffs, which have thrown down a gauntlet to the existing economic models underpinning modern pharmaceutical manufacturing. The generic medicines industry operates on razor-thin margins, with intense competition driving prices toward production costs. Industry data reveals [1] that generic medicines saved the US healthcare system $445 billion in 2023 alone, with biosimilars helping to save an additional $21 billion. Even the modest price increases brought on by tariffs threaten to eliminate these savings altogether, forcing companies into the difficult choice between absorbing costs that destroy profitability, passing the cost onto patients and payers, or restructuring supply chains to avoid exposure to tariffs altogether.
The immediate impact has been severe to say the least, with increasing pressure being placed on the industry to diversify its manufacturing away from tariff-exposed regions, while simultaneously managing existing supply commitments, regulatory requirements, and quality standards. As pharmaceutical manufacturing requires extensive validation, regulatory approvals and quality assurance measures, it would be nothing short of impossible for this transition to occur overnight.
New Dependencies, Potential Vulnerabilities
As well as creating immediate financial pressures, tariffs exposed a deeper issue: the industry's profound dependency on Chinese manufacturing for active pharmaceutical ingredients (APIs), intermediates and finished dosage forms. According to FDA analysis, [2] approximately 80% of API manufacturing facilities supplying the US market are located outside the United States, with the largest concentrations being in China and India.
This dependency creates multiple risks beyond tariff exposure. Geopolitical tensions between China and Western nations raise concerns about supply security during international conflicts or diplomatic disputes. Quality control challenges have already been identified, with incidents of contamination and manufacturing violations highlighting inherent risks in geographically concentrated supply chains. What’s more, the regulatory divergence between standards in China and the West make compliance more challenging, and not to mention persistent concerns over intellectual property related to technology transfer and proprietary manufacturing processes.
The COVID-19 pandemic offered something of a preview of these dependency risks when Chinese manufacturing shutdowns created immediate shortages of essential medicines and APIs. Research published in pharmaceutical journals [3] demonstrates that supply chain disruptions during the pandemic exposed critical vulnerabilities, with 90% of companies surveyed reporting significant impacts on their operations.
Navigating International Regulatory Requirements
As pharmaceutical companies restructure supply chains to reduce their dependency on Chinese suppliers and mitigate the impact of tariffs, they will also face myriad regulatory changes which significantly complicate their efforts to diversify. Each manufacturing location requires regulatory approval from market authorities in each end-user destination, with requirements varying substantially across jurisdictions. According to regulatory analysis, [4] pharmaceutical companies must navigate Good Manufacturing Practice (GMP) inspections, site qualification processes, regulatory submissions documenting manufacturing changes, stability studies demonstrating product consistency and supply chain validation ensuring quality throughout distribution.
The EMA, FDA and other regulatory authorities maintain distinct requirements, inspection protocols, and approval timelines. Transferring manufacturing from one facility to another, even within the same company, requires extensive documentation, validation studies, and regulatory submissions that can take 12-24 months or more. This regulatory burden makes it extremely challenging to diversify supply chains at speed, forcing companies to plan years in advance and maintain dual sourcing during extended periods of transition.
The EMA's GMP guidelines [5] require pharmaceutical manufacturers to demonstrate robust quality management systems, validated manufacturing processes, comprehensive documentation and continuous monitoring. Similar requirements exist across all major regulatory jurisdictions, creating compliance complexity that multiplies as companies diversify manufacturing across multiple locations.
Building Redundancy and Flexibility into Supply Chain Resilience Strategies
Faced with these converging challenges, leading pharmaceutical companies are implementing comprehensive supply chain resilience strategies that prioritise redundancy, geographic diversification, and operational flexibility over pure cost optimisation. Recent research from McKinsey identified successful strategies incorporating dual or triple sourcing of critical APIs and intermediates, geographic diversification across multiple regions and regulatory jurisdictions, vertical integration for strategically critical materials, inventory buffers for essential medicines and digital supply chain visibility enabling rapid response to disruptions.
These strategies require substantial investment, spanning physical infrastructure including new manufacturing facilities in strategically important locations, technology platforms providing real-time supply chain visibility, supplier qualification and auditing programmes and regulatory submissions in support of manufacturing diversification.
Nearshoring and Friendshoring
A central element of resilience strategies involves geographic rebalancing through nearshoring (relocating manufacturing closer to end markets) and friendshoring (shifting production to geopolitically aligned nations). For example, North American pharma companies are increasingly establishing manufacturing operations in Mexico, [6] while European markets are setting up in Eastern Europe, while Southeast Asia has become a hub for the Asia-Pacific markets.
These locations offer advantages such as lower tariff exposure through regional trade agreements, reduced supply chain transportation time and costs and growing manufacturing capabilities and regulatory maturity. However, nearshoring still presents challenges, including higher labour costs, the need for vertical integration of new supplier ecosystems, regulatory approval requirements for new manufacturing sites and substantial investment in quality assurance systems.
Analysis from Contract Pharma [11] demonstrates that successful nearshoring requires careful evaluation of the total cost of ownership, including logistics, inventory carrying costs, regulatory expenses and risk mitigation value, as well as manufacturing. Companies that focus exclusively on direct manufacturing costs often underestimate the benefits of nearshoring, while those adopting comprehensive total-cost models will quickly see substantial return in their investments, from reduced supply chain risk to improved responsiveness.
